Cardiome Pharma has signed an agreement with Merck and Co Inc to jointly develop vernakalant, a experimental drug to treat atrial fibrillation, in a deal that could be worth more than US$600 M. The deal strengthens Cardiome’s financial position while Merck needs to prop up its cardiovascular franchise.